HUMAN SEMAPHORIN 6A-1 (SEMA6A-A), A GENE INVOLVED IN NEURONAL DEVELOPMENT AND REGENERATION MECHANISMS DURING APOPTOSIS, AND ITS USE AS A POTENTIAL DRUG TARGET

Abstract: Human semaphorin 6A-1, a novel gene involved in neuronal development and regeneration mechanisms, is described.

Description: HUMAN SEMAPHORIN GA-1 (SEMAGA-A) , A GENE INVOLVED IN NEURONAL DEVELOPMENT AND REGENERATION MECHANISMS DURING ADOPTOSIS , AND ITS USE AS A POTENTIAL DRUG TARGET Specification The present invention relates to human semaphorin 6A-1 (SEMA6A- 1 ), a novel gene involved in neuronal development and regeneration mechanisms during apoptosis. Actin binding and filament assembly controlling proteins are essential for cellular events that require a drastic remodelling of cytoskeletal elements during development and apoptosis. Proline-rich proteins of the Ena/VASP family play a crucial role in actin and filament dynamics and have only recently been shown to be clustered to cell surface receptors like Dlar, a tyrosine phosphatase essential for motor axon outgrowth (F.B.Gertler et al., 1 996, Cell 87, 227-239; Z.Wills et al. , 1 999, Neuron 22, 301 -31 2). In the last decade the semaphorins were identified as a protein family displaying secreted ortransmembrane-based repulsive guidance cues critically involved in neuronal development (J.G.Culotti and A. L. Kolodkin, Curr.Op.Neurobiol. , 6, 81 -88) . Therefore, it was an object of the present invention to provide a novel human semaphorin variant. The invention comprises a nucleic acid coding for human semaphorin 6A-1 comprising (a) the nucleotide sequence shown in SEQ ID NO: 1 , (b) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO: 1 within the degeneration of the genetic code, or (c) a sequence which hybridizes with the sequences of (a) or/and (b) under stringent conditions. Surprisingly, the transmembranous human semaphorin 6A-1 ((HSA) SEMA6A-1 ) is capable of a selective binding to members of the Ena/VASP protein family. (HSA)SEMA6A- 1 contains a cytoplasmic stretch at its C- terminal end. This domain shares a striking homology to Zyxin, a protein known to bind Ena/VASP (T.Macalma et al. , 1 996, JBC 271 , 31 470- 31 478; S.Hu and L.F.Reichardt, Neuron 22, 41 9-422) . Thus, the human semaphorin sequence was found to comprise a section which matches with other semaphorin sequences, e.g. murine semaphorin sequences as well as a novel domain at its C-terminal end which is capable of binding to elements attached to the cytoskeleton. Therefore, the invention further comprises a nucleic acid coding for a binding domain of human semaphorin 6A-1 comprising: (a) the nucleotide sequence shown in SEQ ID NO:3,(b) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO:3 within the degeneration of the genetic code, or (c) a sequence which hybridizes with the sequences of (a) or/and (b) under stringent conditions. The term "hybridization under stringent conditions" according to the present invention is used as described by Sambrook et al. (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press ( 1 989), 1 . 1 01 - 1 .1 04) . Preferably, a stringent hybridization according to the present invention is given when after washing for an hour with 1 x SSC and 0.1 % SDS at 50°C, preferably at 55 °C, more preferably at 62°C, and most preferably at 68 °C, and more preferably for 1 hour with 0.2 x SSC and 0.1 % SDS at 50°C, preferably at 55 °C, more preferably at 62°C, and most preferably at 68 °C a positive hybridization signal is still observed. A nucleotide sequence which hybridizes under such washing conditions with the nucleotide sequence shown in SEQ ID NO: 1 or with a nucleotide sequence corresponding thereto within the degeneration of the genetic code is a nucleotide sequence according to the invention. The nucleic acid according to the invention preferably is in operative association with an expression control sequence that is active in eukaroytic cells, preferably in mammal cells. The nucleotide sequence according to the invention preferably is a DNA. However, it may also be an RNA or a nucleic acid analog, such as a peptidic nucleic acid. The nucleic acid according to the invention preferably comprises a sequence having a homology of greater than 80%, preferably greater than 90%, and more preferably greater than 95% and, in particular, greater than 97% to the nucleotide sequence according to SEQ ID NO: 1 . The term homology as used herein can be defined by the equation H(%) = [ 1 -V/X] • 1 00, wherein H means homology, X is the total number of nucleobases of the nucleotide sequence according to SEQ ID NO: 1 and V is the number of different nucleobases of a comparative sequence with regard to the nucleotide sequence according to SEQ ID NO: 1 . The invention further comprises a polypeptide encoded by a nucleic acid according to the invention. Such a polypeptide is, in particular, capable of binding to members of the Ena/VASP protein family. The transmembranous SEMA6A-1 is capable of selectively binding to Evl but not Mena, both members of the Ena/VASP protein family. The nucleic acids according to the invention can be obtained using known techniques, e.g. using short sections of the nucleotide sequence shown in SEQ ID NO: 1 as hybridization probe or/and primer. They can, however, also be produced by chemical synthesis. The invention further comprises a recombinant vector containing at least one copy of the nucleic acid according to the invention. This vector may be a prokaryotic or a eukaryotic vector which contains the nucleic acid according to the invention under the control of an expression signal (promoter, operator, enhancer etc.). Examples of prokaryotic vectors are chromosomal vectors such as bacteriophages and extra-chromosomal vectors such as plasmids, circulary plasmid vectors being particularly preferred. Prokaryotic vectors useful according to the present invention are, e.g., described in Sambrook et al. , supra, chapter 1 -4. More preferably, the vector according to the invention is a eukaryotic vector, in particular a vector for mammal cells. Most preferred are vectors suitable for gene therapy, such as retrovirus, modified adenovirus or adeno- associated virus. Such vectors are known to the man skilled in the art of molecular biology and gene therapy and are also described in Sambrook et al., supra, chapter 1 6. In addition to the polypeptide encoded by the nucleic acid of SEQ ID NO: 1 or SEQ ID NO:3, the invention also relates to polypeptides differing therefrom by substitutions, deletions or/and insertions of single amino acids or short amino acid sections. The polypeptide is obtainable by expression of the nucleic acid sequence in a suitable expression system (cf. Sambrook et al., supra) . The polypeptide encoded by SEQ ID NO: 1 is (HSA)SEMA6A- 1 , a new semaphorin variant containing a Zyxin-like domain that binds to the Ena/VASP-like protein (Evl) . In particular, the semaphorins are a protein family displaying secreted ortransmembrane-based repulsive guidance cues critically involved in neuronal development. The polypeptide encoded by SEQ ID NO:3 is a binding domain. This domain can bind selectively to Evl, a member of the Ena/VASP protein family. It may be particularly favorable to combine this binding domain with other proteins having known functionality to give a fusion protein. This binding domain can be used advantageously, alone or as part of a fusion protein, as a means for screening and as a diagnostic and therapeutic target. The invention further comprises a cell transformed with a nucleic acid or a vector according to the invention. The cell may be a eukaryotic or a prokaryotic cell, eukaryotic cells being preferred. The present invention also comprises the use of the polypeptide or fragments thereof as immunogen for the production of antibodies. Standard protocols for obtaining antibodies may be used. The present invention also comprises a pharmaceutical composition comprising a nucleic acid, modified nucleic acid, vector, cell, polypeptide or antibody as defined herein as active component. The pharmaceutical composition may comprise pharmaceutically acceptable carriers, vehicles and/or additives and additional active components, if desired. The pharmaceutical composition can be used for diagnostic purposes or for the production of therapeutic agents. Particularly preferred is the use as a therapeutic agent for the modulation of the immune system. Since the human semaphorin 6A- 1 gene is involved in neuronal development and regeneration mechanisms during apoptosis, this gene can be used to design drug target structures. Members of the semaphorin gene family act as guidance signals and regulatory molecules during neuronal development. Besides its role in development, semaphorin has essential functions in the immune system. Semaphorin can also be linked to potential cancer, drug resistance and disease genes. On the basis of a phylogenetic approach, the semaphorin gene family is currently distinguished into eight classes containing invertebrate (classes 1 , 2) and vertebrate proteins (classes 3-7) . Consistent with this nomenclature, the newly identified semaphorin is grouped into class 6 as human semaphorin 6A- 1 . RNA expression studies have revealed SEMA6A- 1 expression in areas consistent with a role of SEMA6A-1 as a guidance and regulatory signal during development and regeneration. Specialized domains in the cytoplasmic tail of the SEMA6A-1 gene product containing cytoskeletal binding elements show that SEMA6A-1 is also involved in differentiation, cytoskeletal stabilization and plasticity. Finally, the invention is also directed to the use of the herein described pharmaceutical compositions for effecting differentiation, cytoskeletal stabilization and/or plasticity. The invention is further described by the appended figures and examples, wherein Figure 1 shows SEQ ID NO: 1 , the coding nucleotide sequence of the human semaphorin 6A- 1 gene. Figure 2 shows the nucleotide sequence of the human semaphorin 6A- 1 gene as well as the derived amino acid sequence thereof; Figure 3 shows the tissue distribution of (HSA) SEMA6A- 1 revealed by Northern blot hybridizations of human embryo brain, lung, liver, kidney and human adult heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas tissue, respectively; Figure 4 shows the (MMU)Sema6A-1 distribution in mouse adult and embryonic tissues revealed by in-situ hybridizations; Figure 5 shows expression, protein size and dimerization of (HSA)SEMA6A-1 ; Figure 6 shows a sequence alignment between SEMA6A- 1 and Zyxin, wherein Figure 6a shows SEQ ID NO:3, the coding nucleotide sequence to a binding domain and Figure 6b shows the sequence of Zyxin; Figure 7 shows immunoprecipitation of (HSA)SEMA6A-1 with σ-EvI and σ-Mena antibodies. A (σ-EvI) : Vector only (lane 1 ) , pFlagSEMA6A-1 (lane 2) , HT22 supplemented with purified SEMA6A- 1 protein (lane 3) , pFlagSEMA6A-1 precipitation using only protein A beads (lane 4), control detection of pFlagSEMA6A- 1 transfected cells (lane 5), SEMA6A- 1 purified control (lane 6), untransfected HT22 control (lane 7), Evl control in HT22 (lane 8); B (σ-Mena) : Vector only (lane 1 ), pFlagSEMA6A-1 (lane 2), HT22 supplemented with purified SEMA6A-1 protein (lane 3) , control detection of pFlagSEMA6A-1 transfected cells (lane 4); Figure 8 gives a graphical overview on the known Ena/VASP interacting proteins like Zyxin, Dlar and (HSA)SEMA6A-1 . Examples Example 1 Cloning, genomic localization and tissue distribution of (HSA)SEMA6A-1 To identify and isolate repulsive guidance cues that might be involved in neuronal apoptosis a low stringency PCR-approach on cDNA from the human neuroblastoma cell line SK-N-MC was performed and a fragment of (HSA)SEMA6A-1 was amplified. This fragment was used to screen a human 1 -ZAP Express cDNA library. Sequencing of 4 isolated clones revealed an ORF of 3093 bp referring to a protein of 1 030 amino acids in total length with a predicted size of 1 35 kDa. (Fig.2: Nucleic acid sequence and deduced amino acid sequence) . Database searches identified 43 unordered sequences (Genbank Ace. -No. AC008524) and a mapped genomic survey sequence (Genbank Ace. -No. AB002453) of human chromosome 5 localizing the gene to 5q21 -22. Gaps between the genomic sequences were closed by PCR on human genomic DNA and subsequent sequencing. The (hsa)sema6A-1 gene covers 45 kb of genomic sequence and consists of 1 8 exons including 1 untranslated exon at the 3'-end (see Figure 2) . Example 2 Similarity and domain structure of (HSA)SEMA6A-1 Database searches revealed that SEMA6A- 1 ( 1 030aa) has a relatively high similarity to its murine ortholog Sema6A-1 (869aa) within the overlapping region consisting of 869aa. The existence of an additional cytoplasmic domain prompted us to name the new protein SEMA6A- 1 . This unique domain shares a 33% identity (49% similarity) to Zyxin, a proline-rich protein present at focal adhesion points and capable of binding to members of the Ena/VASP family. Binding of Zyxin to Ena/VASP occurs via a peptide stretch displaying the sequence DFPPPP (K.E.Prehoda et al., 1 999, Cell 97, 471 -480) . (HSA)SEMA6A-1 contains two potential binding motifs (aa 858- 962 (DNPPP) and aa 1 01 0- 1 01 5 (DVPPKP) in its Zyxin homologous domain that are similar to the above-mentioned motif. Example 3 Tissue distribution of (HSA)SEMA6A-1 revealed by Northern blot and in situ hybridization Northern blot hybridizations of poly A + RNA of human adult and embryonic tissues detected two transcripts in the molecular range of 4.5 kb and 7 kb. Highest levels of detection were present in embryonic brain and kidney, moderate expression in lung and virtually no expression in liver. Compared to embryonic levels there was observed a clear reduction of expression of (HSA)SEMA6A- 1 in adult tissues with the exception of placenta. In situ hybridizations in mouse embryo revealed a distinct expression throughout the whole embryo that is restricted to nervous system areas. These results indicate a general role of this protein in development and are shown in Figures 3 and 4: Figure 3 shows the human Northern blots. Figure 4 displays in situ hybridizations of embryonic (A, B, C, D) and adult (E, F, G) tissues. Notify the dominant expression in embryonic brain stem (A, B, D), optic precursors (A, C), spinal cord (B, D) and limb (B) . High expression levels in adult regions are maintained in piriform cortex (E) , cerebellar regions (F, G) and olfactory bulb (G) . Example 4 Expression of (HSA)SEMA6A-1 in mammalian cell lines In order to show that Ena/VASP proteins might be potential intracellular binding partners for (HSA)SEMA6A-1 (see Figure 6, Alignment of (HSA)SEMA6A- 1 and Zyxin) and that (HSA)SEMA6A-1 and Ena/VASP-like proteins might be interacting partners a Xbal/Scal fragment of the SEMA6A- 1 clone covering the full length protein sequence only lacking the signal sequence was subcloned into the pFLAG-CMV-1 vector. This vector allows rapid detection of the expressed fusion protein through the N-terminal Flag- Taq fused to the protein. Immunoblotting of the tagged protein (Flag-SEMA6A-1 ) displayed a protein size of 1 25 kDa which closely corresponds to the predicted protein size. Expression in a human cell line (HEK293) and in a clonal mouse hippocampal cell line (HT22) followed by immunofluorescent analysis revealed that SEMA6A-1 is targeted to the cell surface and colocalizes with Evl and Mena, indicating a possible interaction between these proteins (see Figure 5, showing a graphical overview on the domain structure of (HSA)SEMA6A-1 and the subcloning strategy. In addition, Western blots displaying the protein size and its dimerization abilities are shown) . Example 5 Immunoprecipitation of (HSA)SEMA6A-1 Using antibodies specific for Mena and Evl Flag-SEMA6A-1 was immunoprecipitated from Triton X-1 00 extracts of transfected HEK239 and HT22 cells. The precipitate was separated by SDS-PAGE, and subsequent immunoblotting with the monoclonal anti-Flag antibody revealed that Flag- SEMA6A- 1 co-immunoprecipitates with Evl but not Mena. To confirm this interaction Flag-SEMA6A-1 was purified from transfected HEK293 cells on an anti-Flag affinity column and the Triton X-1 00 extract of untransfected HT22 cells was supplemented with the purified protein, followed by immunoprecipiation of the protein complex using the σ-EvI antibody. Immunoblotting again revealed that FlagSEMA6A-1 co-precipitates Evl. Figure 7 shows the immunoprecipitation experiments using the σ-EvI- and σ-Mena antibodies. SEQUENCE LISTING <110> Max-Planc -Gesellschaft zur Foerderung der Wissens <120> Human semaphorin 6A-1 (SEMA6A-1), a novel gene involved in neuronal development and regeneration mechanisms during apoptosis, as a potential drug target structure <130> 19592 <140> <141> <150> 98122441.3 <151> 1998-11-26 <160> 7 <170> Patentln Ver. 2.1 <210> 1 <211> 3093 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (1) .. (3093) <400> 1 atg agg tea gaa gcc ttg ctg eta tat ttc aca ctg era cac ttt get 48 Met Arg Ser Glu Ala Leu Leu Leu Tyr Phe Thr Leu Leu His Phe Ala 1 5 10 15 ggg get ggt ttc cca gaa gat tct gag cca ate agt att teg cat ggc 96 Gly Ala Gly Phe Pro Glu Asp Ser Glu Pro He Ser He Ser His Gly 20 25 30 aac tat aca aaa cag tat ccg gtg ttt gtg ggc cac aag cca gga egg 144 Asn Tyr Thr Lys Gin Tyr Pro Val Phe Val Gly His Lys Pro Gly Arg 35 40 45 aac ace aca cag agg cac agg ctg gac ate cag atg att atg ate atg 192 Asn Thr Thr Gin Arg His Arg Leu Asp He Gin Met He Met He Met 50 55 60 aac gga ace etc tac att get get agg gac cat att tat act gtt gat 240 Asn G y Thr Leu Tyr He Ala Ala Arg Asp His He Tyr Thr Val Asp 65 70 75 80 ata gac aca tea cac acg gaa gaa att tat tgt age aaa aaa ctg aca 288 He Asp Thr Ser His Thr Glu Glu He Tyr Cys Ser Lys Lys Leu Thr 85 90 95 tgg aaa tct aga cag gee gat gta gac aca tgc aga atg aag gga aaa 336 Trp Lys Ser Arg Gin Ala Asp Val Asp Thr Cys Arg Met Lys Gly Lys 100 105 110 cat aag gat gag tgc cac aac ttt att aaa gtt ctt cca aag aaa aac 384 His Lys Asp Glu Cys His Asn Phe He Lys Val Leu Leu Lys Lys Asn 115 120 125 gar gat gca ttg ttt gtc tgt gga act aat gee ttc aac cct tec tgc 432 Asp Asp Ala Leu Phe Val Cys Gly Thr Asn Ala Phe Asn Pro Ser Cys 130 135 140 aga aac tat aag atg gat aca ttg gaa cca ttc ggg gat gaa ttc age 480 Arg Asn Tyr Lys Met Asp Thr Leu Glu Pro Phe Gly Asp Glu Phe Ser 145 150 155 160 gga atg gcc aga tgc cca tat gat gee aaa cat gee aac gtt gca ctg 528 Gly Met Ala Arg Cys Pro Tyr Asp Ala Lys His Ala Asn Val Ala Leu 165 170 175 ttt gca gat gga aaa eta tac tea gcc aca gtg act gac ttc ctt gcc 576 Phe Ala Asp Gly Lys Leu Tyr Ser Ala Thr Val Thr Asp Phe Leu Ala 180 185 190 att gac gca gtc att tac egg agr ctt gga gaa age cct ace ctg egg 624 lie Asp Ala Val He Tyr Arg Ser Leu Gly Glu Ser Pro Thr Leu Arg 195 200 205 ace gtc aag cac gat tea aaa tgg ttg aaa gaa cca tac ttt gtt caa 672 Thr Val Lys His Asp Ser Lys Trp Leu Lys Glu Pro Tyr Phe Val Gin 210 215 220 gcc gtg gat tac gga gat tat ate tac ttc ttc ttc agg gaa ata gca 720 Ala Val Asp Tyr Gly Asp Tyr He Tyr Phe Phe Phe Arg Glu He Ala 225 230 235 240 gtg gag tat aac ace atg gga aag gta gtt ttc cca aga gtg get cag 768 Val Glu Tyr Asn Thr Met Gly Lys Val Val Phe Pro Arg Val Ala Gin 245 250 255 gtt tgt aag aat gat atg gga gga tct caa aga gtc erg gag aaa cag 816 Val Cys Lys Asn Asp Mer Gly Gly Ser Gin Arg Val Leu Glu Lys Gin 2 260 265 270 tgg acg teg ttc ctg aag gcg cgc ttg aac rgc rca gtt cct gga gac 864 Trp Thr Ser Phe Leu Lys Ala Arg Leu Asn Cys Ser Val Pro Gly Asp 275 280 285 tct cat ttt tat ttc aac att etc cag gca gtt aca gat gtg att cgt 912 Ser His Phe Tyr Phe Asn He Leu Gin Ala Val Thr Asp Val He Arg 290 295 300 arc aac ggg cgt gat gtt gtc ctg gca acg ttt tcr aca cct tat aac 960 He Asn Gly Arg Asp Val Val Leu Ala Thr Phe Ser Thr Pro Tyr Asn 305 310 315 320 age ate cct ggg tct gca gtc tgt gcc tat gac atg ctt gac att gcc 1008 Ser He Pro Gly Ser Ala Val Cys Ala Tyr Asp Met Leu Asp He Ala 325 330 335 agr gtt ttt act ggg aga ttc aag gaa cag aag rcr ccr gat tec ace 1056 Ser Val Phe Thr Gly Arg Phe Lys Glu Gin Lys Ser Pro Asp Ser Thr 340 345 350 tgg aca cca gtt cct gat gaa cga gtt cct aag ccc agg cca ggt tgc 1104 Trp Thr Pro Val Pro Asp Glu Arg Val Pro Lys Pro Arg Pro Gly Cys 355 360 365 tgr get ggc tea tec tec tta gaa aga rat gca ace tec aat gag ttc 1152 Cys Ala Gly Ser Ser Ser Leu Glu Arg Tyr Ala Thr Ser Asn Glu Phe 370 375 380 cct gat gat ace ctg aac ttc ate aag acg cac ccg etc atg gat gag 1200 Pro Asp Asp Thr Leu Asn Phe He Lys Thr His Pro Leu Met Asp Glu 385 390 395 400 gca gtg ccc tec ate ttc aac agg cca rgg ttc erg aga aca atg gtc 1248 Ala Val Pro Ser He Phe Asn Arg Pro Trp Phe Leu Arg Thr Met Val 405 410 415 aga tac cgc ctt ace aaa att gca gtg gac aca get get ggg cca tat 1296 Arg Tyr Arg Leu Thr Lys He Ala Val Asp Thr Ala Ala Gly Pro Tyr 420 425 430 cag aat cac act gtg gtt ttt ctg gga tea gag aag gga ate ate ttg 1344 Gin Asn His Thr Val Val Phe Leu Gly Ser Glu Lys Gly He He Leu 435 440 445 aag ttt ttg gcc aga ata gga aat agt ggt trt eta aat gac age ctt 1392 Lys Phe Leu Ala Arg He Gly Asn Ser Gly Phe Leu Asn Asp Ser Leu 450 455 460 ttc erg gag gag atg agt gtt tac aac tct gaa aaa tgc age tat gat 1440 Phe Leu Glu Glu Met Ser Val Tyr Asn Ser Glu Lys Cys Ser Tyr Asp 465 470 475 480 gga gtc gaa gac aaa agg ate atg ggc atg cag ctg gac aga gca age 1488 Gly Val Glu Asp Lys Arg He Met Gly Met Gin Leu Asp Arg Ala Ser 485 490 495 age tct ctg tat gtt gcg ttc tct ace tgt gtg ata aag gtt ccc ctt 1536 Ser Ser Leu Tyr Val Ala Phe Ser Thr Cys Val He Lys Val Pro Leu 500 505 510 ggc egg tgt gaa cga cat ggg aag tgt aaa aaa ace tgt att gcc tec 1584 Gly Arg Cys Glu Arg His Gly Lys Cys Lys Lys Thr Cys He Ala Ser 515 520 525 aga gac cca tat tgt gga tgg ata aag gaa ggt ggt gcc tgc age cat 1632 Arg Asp Pro Tyr Cys Gly Trp He Lys Glu Gly Gly Ala Cys Ser His 530 535 540 tta tea ccc aac age aga ctg act ttt gag cag gac ata gag cgt ggc 1680 Leu Ser Pro Asn Ser Arg Leu Thr Phe Glu Gin Asp He Glu Arg Gly 545 550 555 560 aat aca gat ggt ctg ggg gac tgt cac aat tec ttt gtg gca ctg aat 1728 Asn Thr Asp Gly Leu Gly Asp Cys His Asn Ser Phe Val Ala Leu Asn 565 570 575 ggg cat tec agt tec etc ttg ccc age aca ace aca tea gat teg acg 1776 Gly His Ser Ser Ser Leu Leu Pro Ser Thr Thr Thr Ser Asp Ser Thr 580 585 590 get caa gag ggg tat gag tct agg gga gga atg ctg gac tgg aag cat 1824 Ala Gin Glu Gly Tyr Glu Ser Arg Gly Gly Met Leu Asp Trp Lys His 595 600 605 ctg crt gac tea cct gac age aca gac cct ttg ggg gca gtg tct tec 1872 Leu Leu Asp Ser Pro Asp Ser Thr Asp Pro Leu Gly Ala Val Ser Ser 610 615 620 cat aat cac caa gac aag aag gga gtg art egg gaa agt tac etc aaa 1920 His Asn His Gin Asp Lys Lys Gly Val He Arg Glu Ser Tyr Leu Lys 625 630 635 640 ggc cac gac cag ctg gtt ccc gtc ace etc ttg gcc att gca gtc ate 1968 Gly His Asp Gin Leu Val Pro Val Thr Leu Leu Ala He Ala Val He 645 650 655 ctg get ttc gtc atg ggg gcc gtc ttc teg ggc ate -ace gtc tac tgc 2016 Leu Ala Phe Val Met Gly Ala Val Phe Ser Gly He Thr Val Tyr Cys 660 665 670 gtc tgt gat cat egg cgc aaa gac gtg get gtg gtg cag cgc aag gag 2064 Val Cys Asp His Arg Arg Lys Asp Val Ala Val Val Gin Arg Lys Glu 675 680 685 aag gag etc ace cac teg cgc egg ggc tec atg age age grc ace aag 2112 Lys Glu Leu Thr His Ser Arg Arg Gly Ser Met Ser Ser Val Thr Lys 690 695 700 etc age ggc etc ttt ggg gac act caa tec aaa gac cca aag ccg gag 2160 Leu Ser Gly Leu Phe Gly Asp Thr Gin Ser Lys Asp Pro Lys Pro Glu 705 710 715 720 gcc ate etc acg cca etc atg cac aac ggc aag etc gcc act ccc ggc 2208 Ala He Leu Thr Pro Leu Met His Asn Gly Lys Leu Ala Thr Pro Gly 725 730 735 aac acg gcc aag atg etc att aaa gca gac cag cac cac ctg gac ctg 2256 Asn Thr Ala Lys Met Leu He Lys Ala Asp Gin His His Leu Asp Leu 740 745 750 acg gcc etc ccc ace cca gag tea ace cca acg ctg cag cag aag egg 2304 Thr Ala Leu Pro Thr Pro Glu Ser Thr Pro Thr Leu Gin Gin Lys Arg 755 760 765 aag ccc age cgc ggc age cgc gag tgg gag agg aac cag aac etc ate 2352 Lys Pro Ser Arg Gly Ser Arg Glu Trp Glu Arg Asn Gin Asn Leu He 770 775 780 aat gcc tgc aca aag gac atg ccc ccc atg ggc tec ccr gtg att ccc 2400 Asn Ala Cys Thr Lys Asp Met Pro Pro Met Gly Ser Pro Val He Pro 785 790 795 800 acg gac ctg ccc ctg egg gcc tec ccc age cac ate ccc age gtg gtg 2448 Thr Asp Leu Pro Leu Arg Ala Ser Pro Ser His He Pro Ser Val Val 805 810 815 gtc ctg ccc ate acg cag cag ggc tac cag cat gag tac gtg gac cag 2496 Val Leu Pro He Thr Gin Gin Gly Tyr Gin His Glu Tyr Val Asp Gin 820 825 830 ccc aaa atg age gag gtg gcc cag atg gcg ctg gag gac cag gcc gcc 2544 Pro Lys Met Ser Glu Val Ala Gin Met Ala Leu Glu Asp Gin Ala Ala 835 840 845 aca ctg gag tat aag ace ate aag gaa cat etc age age aag agt ccc 2592 Tnr Leu Glu Tyr Lys Thr He Lys Glu His Leu Ser Ser Lys Ser Pro 850 855 860 aac cat ggg gtg aac ctt gtg gag aac ctg gac age ctg ccc ccc aaa 2640 Asn His Gly Val Asn Leu Val Glu Asn Leu Asp Ser Leu Pro Pro Lys 865 870 875 880 gtr cca cag egg gag gcc tec ctg ggt ccc ccg gga gcc tec ctg tcr 2688 Val Pro Gin Arg Glu Ala Ser Leu Gly Pro Pro Gly Ala Ser Leu Ser 885 890 895 cag ace ggt eta age aag egg ctg gaa atg cac cac tec tct tec tac 2736 Gin Thr Gly Leu Ser Lys Arg Leu Glu Met His His Ser Ser Ser Tyr 900 905 910 ggg gtt gac tat aag agg age tac ccc acg aac teg etc acg aga age 2784 Gly Val Asp Tyr Lys Arg Ser Tyr Pro Thr Asn Ser Leu Thr Arg Ser 915 920 925 cac cag gcc ace act etc aaa aga aac aac acr aac tec tec aat tec 2832 His Gin Ala Thr Thr Leu Lys Arg Asn Asn Tnr Asn Ser Ser Asn Ser 930 935 940 tct cac etc tec aga aac cag age ttt ggc agg gga gac aac ccg ccg 2880 Ser His Leu Ser Arg Asn Gin Ser Phe Gly Arg Gly Asp Asn Pro Pro 945 950 955 960 ccc gcc ccg cag agg gtg gac tec ate cag gtg cac age tec cag cca 2928 Pro Ala Pro Gin Arg Val Asp Ser He Gin Val His Ser Ser Gin Pro 965 970 975 tct ggc cag gcc gtg act gtc teg agg cag ccc age etc aac gcc tac 2976 Ser Gly Gin Ala Val Thr Val Ser Arg Gin Pro Ser Leu Asn Ala Tyr 980 985 990 aac tea ctg aca agg teg ggg ctg aag cgt acg ccc teg eta aag ccg 3024 Asn Ser Leu Thr Arg Ser Gly Leu Lys Arg Thr Pro Ser Leu Lys Pro 995 1000 1005 gac gta ccc ccc aaa cca tec ttt get ccc ctt tec aca tec atg aag 3072 Asp Val Pro Pro Lys Pro Ser Phe Ala Pro Leu Ser Thr Ser Met Lys 1010 1015 1020 ccc aat gat gcg tgt aca taa 3093 Pro Asn Asp Ala Cys Thr 1025 1030 <210> 2 <211> 1030 <212> PRT <213> Homo sapiens <400> 2 Met Arg Ser Glu Ala Leu Leu Leu Tyr Phe Thr Leu Leu His Phe Ala 1 5 10 15 Gly Ala Gly Phe Pro Glu Asp Ser Glu Pro He Ser He Ser His Gly 20 25 30 Asn Tyr Thr Lys Gin Tyr Pro Val Phe Val Gly His Lys Pro Gly Arg 35 40 45 Asn Thr Thr Gin Arg His Arg Leu Asp He Gin Met He Met He Met 50 55 60 Asn Gly Thr Leu Tyr He Ala Ala Arg Asp His He Tyr Thr Val Asp 65 70 75 80 He Asp Thr Ser His Thr Glu Glu He Tyr Cys Ser Lys Lys Leu Thr 85 90 95 Trp Lys Ser Arg Gin Ala Asp Val Asp Thr Cys Arg Met Lys Gly Lys 100 105 110 His Lys Asp Glu Cys His Asn Phe He Lys Val Leu Leu Lys Lys Asn 115 120 125 Asp Asp Ala Leu Phe Val Cys Gly Thr Asn Ala Phe Asn Pro Ser Cys 130 135 140 Arg Asn Tyr Lys Met Asp Thr Leu Glu Pro Phe Gly Asp Glu Phe Ser 145 150 155 160 Gly Met Ala Arg Cys Pro Tyr Asp Ala Lys His Ala Asn Val Ala Leu 165 170 175 Phe Ala Asp Gly Lys Leu Tyr Ser Ala Thr Val Thr Asp Phe Leu Ala 180 185 190 He Asp Ala Val He Tyr Arg Ser Leu Gly Glu Ser Pro Thr Leu Arg 195 200 205 Thr Val Lys His Asp Ser Lys Trp Leu Lys Glu Pro Tyr Phe Val Gin 210 215 220 Ala Val Asp Tyr Gly Asp Tyr He Tyr Phe Phe Phe Arg Glu He Ala 225 230 235 240 Val Glu Tyr Asn Thr Met Gly Lys Val Val Phe Pro Arg Val Ala Gin 245 250 255 Val Cys Lys Asn Asp Met Gly Gly Ser Gin Arg Val Leu Glu Lys Gin 260 265 270 Trp Thr Ser Phe Leu Lys Ala Arg Leu Asn Cys Ser Val Pro Gly Asp 275 280 285 Ser His Phe Tyr Phe Asn He Leu Gin Ala Val Thr Asp Val He Arg 290 295 300 He Asn Gly Arg Asp Val Val Leu Ala Thr Phe Ser Thr Pro Tyr Asn 305 310 315 320 Ser He Pro Gly Ser Ala Val Cys Ala Tyr Asp Met Leu Asp He Ala 325 330 335 Ser Val Phe Thr Gly Arg Phe Lys Glu Gin Lys Ser Pro Asp Ser Thr 340 345 350 Trp Thr Pro Val Pro Asp Glu Arg Val Pro Lys Pro Arg Pro Gly Cys 355 360 365 Cys Ala Gly Ser Ser Ser Leu Glu Arg Tyr Ala Thr Ser Asn Glu Phe 370 375 380 Pro Asp Asp Thr Leu Asn Phe He Lys Thr His Pro Leu Met Asp Glu 385 390 395 400 Ala Val Pro Ser He Phe Asn Arg Pro Trp Phe Leu Arg Thr Met Val 405 410 415 Arg Tyr Arg Leu Thr Lys He Ala Val Asp Thr Ala Ala Gly Pro Tyr 420 425 430 Gin Asn His Thr Val Val Phe Leu Gly Ser Glu Lys Gly He He Leu 435 440 445 Lys Phe Leu Ala Arg He Gly Asn Ser Gly Phe Leu Asn Asp Ser Leu 450 455 460 Phe Leu Glu Glu Met Ser Val Tyr Asn Ser Glu Lys Cys Ser Tyr Asp 465 470 475 480 Gly Val Glu Asp Lys Arg He Met Gly Met Gin Leu Asp Arg Ala Ser 485 490 495 Ser Ser Leu Tyr Val Ala Phe Ser Thr Cys Val He Lys Val Pro Leu 500 505 510 Gly Arg Cys Glu Arg His Gly Lys Cys Lys Lys Thr Cys He Ala Ser 515 520 525 Arg Asp Pro Tyr Cys Gly Trp He Lys Glu Gly Gly Ala Cys Ser His 530 535 540 Leu Ser Pro Asn Ser Arg Leu Thr Phe Glu Gin Asp He Glu Arg Gly 545 550 555 560 Asn Thr Asp Gly Leu Gly Asp Cys His Asn Ser Phe Val Ala Leu Asn 565 570 575 Gly His Ser Ser Ser Leu Leu Pro Ser Thr Thr Thr Ser Asp Ser Thr 580 585 590 Ala Gin Glu Gly Tyr Glu Ser Arg Gly Gly Met Leu Asp Trp Lys His 595 600 605 Leu Leu Asp Ser Pro Asp Ser Thr Asp Pro Leu Gly Ala Val Ser Ser 610 615 620 His Asn His Gin Asp Lys Lys Gly Val He Arg Glu Ser Tyr Leu Lys 62~5 630 635 640 Gly His Asp Gin Leu Val Pro Val Thr Leu Leu Ala He Ala Val He 645 650 655 Leu Ala Phe Val Met Gly Ala Val Phe Ser Gly He Thr Val Tyr Cys 660 665 670 Val Cys Asp His Arg Arg Lys Asp Val Ala Val Val Gin Arg Lys Glu 675 680 685 Lys Glu Leu Thr His Ser Arg Arg Gly Ser Met Ser Ser Val Thr Lys 690 695 700 Leu Ser Gly Leu Phe Gly Asp Thr Gin Ser Lys Asp Pro Lys Pro Glu 705 710 715 720 Ala He Leu Thr Pro Leu Met His Asn Gly Lys Leu Ala Thr Pro Gly 725 730 735 Asn Thr Ala Lys Met Leu He Lys Ala Asp Gin His His Leu Asp Leu 740 745 750 Thr Ala Leu Pro Thr Pro Glu Ser Thr Pro Thr Leu Gin Gin Lys Arg 755 760 765 Lys Pro Ser Arg Gly Ser Arg Glu Trp Glu Arg Asn Gin Asn Leu He 770 775 780 Asn Ala Cys Thr Lys Asp Met Pro Pro Met Gly Ser Pro Val He Pro 785 790 795 800 Thr Asp Leu Pro Leu Arg Ala Ser Pro Ser His He Pro Ser Val Val 805 810 815 Val Leu Pro He Thr Gin Gin Gly Tyr Gin His Glu Tyr Val Asp Gin 820 825 830 Pro Lys Met Ser Glu Val Ala Gin Met Ala Leu Glu Asp Gin Ala Ala 835 840 845 Thr Leu Glu Tyr Lys Thr He Lys Glu His Leu Ser Ser Lys Ser Pro 850 855 860 Asn His Gly Val Asn Leu Val Glu Asn Leu Asp Ser Leu Pro Pro Lys 865 870 875 880 Val Pro Gin Arg Glu Ala Ser Leu Gly Pro Pro Gly Ala Ser Leu Ser 885 890 895 Gin Thr Gly Leu Ser Lys Arg Leu Glu Met His His Ser Ser Ser Tyr 900 905 910 Gly Val Asp Tyr Lys Arg Ser Tyr Pro Thr Asn Ser Leu Thr Arg Ser 915 920 925 His Gin Ala Thr Thr Leu Lys Arg Asn Asn Thr Asn Ser Ser Asn Ser 930 935 940 Ser His Leu Ser Arg Asn Gin Ser Phe Gly Arg Gly Asp Asn Pro Pro 945 950 955 960 Pro Ala Pro Gin Arg Val Asp Ser He Gin Val His Ser Ser Gin Pro 965 970 975 10 Ser Gly Gin Ala Val Thr Val Ser Arg Gin Pro Ser Leu Asn Ala Tyr 980 985 990 Asn Ser Leu Thr Arg Ser Gly Leu Lys Arg Thr Pro Ser Leu Lys Pro 995 1000 1005 Asp Val Pro Pro Lys Pro Ser Phe Ala Pro Leu Ser Thr Ser Met Lys 1010 1015 1020 Pro Asn Asp Ala Cys Thr 025 1030 <210> 3 <211> 216 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (1) .. (216) <400> 3 ccg ccg ccc gcc ccg cag agg gtg gac tec ate cag gtg cac age tec 48 Pro Pro Pro Ala Pro Gin Arg Val Asp Ser He Gin Val His Ser Ser 1 5 10 15 cag cca tct ggc cag gcc gtg act gtc teg agg cag ccc age etc aac 96 Gin Pro Ser Gly Gin Ala Val Thr Val Ser Arg Gin Pro Ser Leu Asn 20 25 30 gcc tac aac tea ctg aca agg teg ggg ctg aag cgt acg ccc teg eta 144 Ala Tyr Asn Ser Leu Thr Arg Ser Gly Leu Lys Arg Thr Pro Ser Leu 35 40 45 aag ccg gac gta ccc ccc aaa cca tec ttt get ccc ctt tec aca tec 192 Lys Pro Asp Val Pro Pro Lys Pro Ser Phe Ala Pro Leu Ser Thr Ser 50 55 60 atg aag ccc aat gat gcg tgt aca 216 Met Lys Pro Asn Asp Ala Cys Thr 65 70 <210> 4 <211> 72 <212> PRT 11 <213> Homo sapiens <400> 4 Pro Pro Pro Ala Pro Gin Arg Val Asp Ser He Gin Val His Ser Ser 1 5 10 15 Gin Pro Ser Gly Gin Ala Val Thr Val Ser Arg Gin Pro Ser Leu Asn 20 25 30 Ala Tyr Asn Ser Leu Thr Arg Ser Gly Leu Lys Arg Thr Pro Ser Leu 35 40 45 Lys Pro Asp Val Pro Pro Lys Pro Ser Phe Ala Pro Leu Ser Thr Ser 50 55 60 Met Lys Pro Asn Asp Ala Cys Thr 65 70 <210> 5 <211> 65 <212> PRT <213> Homo sapiens <400> 5 Pro Pro Pro Gin Pro Gin Arg Lys Pro Gin Val Gin Leu His Val Gin 1 5 10 15 Pro Gin Ala Lys Pro His Val Gin Pro Gin Pro Val Ser Ser Ala Asn 20 25 30 Thr Gin Pro Arg Gly Pro Leu Ser Gin Ala Pro Thr Pro Ala Pro Lys 35 40 45 Phe Ala Pro Val Ala Pro Lys Phe Thr Pro Val Val Ser Lys Phe Ser 50 55 60 Pro 65 <210> 6 <211> 3862 <212> DNA <213> Homo sapiens 12 <220> <221 > CDS <222 > ( 658 ) . . ( 3750 ) < 400> 6 ggcacgaggc tgcagccaac tccgctcccc gcgcactcgg ctgcccaggc gctcggaacc 60 cagcagcggc gctcctccgc ggtgccggtc gcccgcgatg cccgcttagc agcgtgtagc 120 agcggccagc atcaccacac ccgcggcacc gcgctgccgg ccgcagagcc gggccagagc 180 cttgcccccc tcccccagcc cccaccccgc cccccgccct gaaatgactt gttaatcggc 240 gcagacacca ccaaggggac tcaccgaagt ggaatccaag tggaatttgg atttggagaa 300 gagrrrcttg aacatttace etetteettg ttggtrttet ttttettttt ettctttttt 360 tttttggctt cttttttccr ctccccttct ccgctcσtca ttggagatga acacatcgcg 420 tttgcatccc agaaagtagt cgccgcgact atttccccca aagagacaag cacacatgta 480 ggaatgacaa aggcttgcga aggagagage cgeageegcg gcccggagag atccectcga 540 taatggatta etaaatggga taeacgctgt aceagttcgc tccgageecc ggeegcctgt 600 ccgtcgatgc accgaaaagg gtgaagtaga gaaataaagt ctccccgctg aactact 657 atg agg tea gaa gcc ttg ctg eta tat ttc aca ctg eta cac ttt get 705 Met Arg Ser Glu Ala Leu Leu Leu Tyr Phe Thr Leu Leu His Phe Ala 1 5 10 15 ggg get ggt ttc cca gaa gat tct gag cca ate agt att teg cat ggc 753 Gly Ala Gly Phe Pro Glu Asp Ser Glu Pro He Ser He Ser His Gly 20 25 30 aac tat aca aaa cag tat ccg gtg ttt gtg ggc cac aag cca gga egg 801 Asn Tyr Thr Lys Gin Tyr Pro Val Phe Val Gly His Lys Pro Gly Arg 35 40 45 aac ace aca cag agg cac agg ctg gac ate cag atg att atg ate atg 849 Asn Thr Thr Gin Arg His Arg Leu Asp He Gin Met He Met He Met 50 55 60 aac gga ace etc tac att get get agg gac cat att tat act gtt gat 897 Asn Gly Thr Leu Tyr He Ala Ala Arg Asp His He Tyr Thr Val Asp 65 70 75 80 ata gac aca tea cac acg gaa gaa att tat tgt age aaa aaa ctg aca 945 13 He Asp Thr Ser His Thr Glu Glu He Tyr Cys Ser Lys Lys Leu Thr 85 90 95 tgg aaa tct aga cag gcc gat gta gac aca tgc aga arg aag gga aaa 993 Trp Lys Ser Arg Gin Ala Asp Val Asp Thr Cys Arg Met Lys Gly Lys 100 105 110 cat aag gar gag tgc cac aac ttt att aaa grt ctt eta aag aaa aac 1041 His Lys Asp Glu Cys His Asn Phe He Lys Val Leu Leu Lys Lys Asn 115 120 125 gat gat gca ttg ttt gtc tgt gga act aat gcc trc aac cct tec tgc 1089 Asp Asp Ala Leu Phe Val Cys Gly Thr Asn Ala Phe Asn Pro Ser Cys 130 135 140 aga aac tat aag atg gat aca ttg gaa cca ttc ggg gat gaa ttc age 1137 Arg Asn Tyr Lys Met Asp Thr Leu Glu Pro Phe Gly Asp Glu Phe Ser 145 150 155 160 gga atg gcc aga tgc cca tat gat gcc aaa cat gcc aac gtt gca ctg 1185 Gly Met Ala Arg Cys Pro Tyr Asp Ala Lys His Ala Asn Val Ala Leu 165 170 175 ttt gca gat gga aaa eta tac tea gcc aca gtg act gac ttc ctt gcc 1233 Phe Ala Asp Gly Lys Leu Tyr Ser Ala Thr Val Thr Asp Phe Leu Ala 180 185 190 att gac gca gtc att tac egg agt ctt gga gaa age cct ace ctg egg 1281 He Asp Ala Val He Tyr Arg Ser Leu Gly Glu Ser Pro Thr Leu Arg 195 200 205 ace gtc aag cac gat tea aaa tgg ttg aaa gaa cca tac ttt gtt caa 1329 Thr Val Lys His Asp Ser Lys Trp Leu Lys Glu Pro Tyr Phe Val Gin 210 215 220 gcc gtg gat tac gga gat tat ate tac ttc ttc ttc agg gaa ata gca 1377 Ala Val Asp Tyr Gly Asp Tyr He Tyr Phe Phe Phe Arg Glu He Ala 225 230 235 240 gtg gag tat aac ace atg gga aag gta gtt ttc cca aga gtg get cag 1425 Val Glu Tyr Asn Thr Met Gly Lys Val Val Phe Pro Arg Val Ala Gin 245 250 255 gtt tgt aag aat gat atg gga gga tct caa aga gtc erg gag aaa cag 1473 Val Cys Lys Asn Asp Met Gly Gly Ser Gin Arg Val Leu Glu Lys Gin 260 265 270 tgg acg teg ttc ctg aag gcg cgc ttg aac tgc tea gtt cct gga gac 1521 14 Trp Thr Ser Phe Leu Lys Ala Arg Leu Asn Cys Ser Val Pro Gly Asp 275 280 285 tcr cat ttt tat ttc aac att etc cag gca gtt aca gat gtg att cgt 1569 Ser His Phe Tyr Phe Asn He Leu Gin Ala Val Thr Asp Val He Arg 290 295 300 arc aac ggg cgt gat gtt gtc ctg gca acg ttt tct aca cct tat aac 1617 He Asn Gly Arg Asp Val Val Leu Ala Thr Phe Ser Thr Pro Tyr Asn 305 310 315 320 age arc cct ggg tct gca gtc rgt gcc tat gac atg err gac att gcc 1665 Ser He Pro Gly Ser Ala Val Cys Ala Tyr Asp Met Leu Asp He Ala 325 330 335 agt gtt ttt act ggg aga ttc aag gaa cag aag tct ccr gat tec ace 1713 Ser Val Phe Thr Gly Arg Phe Lys Glu Gin Lys Ser Pro Asp Ser Thr 340 345 350 tgg aca cca gtt cct gat gaa cga gtt cct aag ccc agg cca ggt tgc 1761 Trp Thr Pro Val Pro Asp Glu Arg Val Pro Lys Pro Arg Pro Gly Cys 355 360 365 tgt get ggc tea tec tec tta gaa aga tat gca ace tec aat gag ttc 1809 Cys Ala Gly Ser Ser Ser Leu Glu Arg Tyr Ala Thr Ser Asn Glu Phe 370 375 380 cct gat gat ace ctg aac ttc ate aag acg cac ccg etc atg gat gag 1857 Pro Asp Asp Thr Leu Asn Phe He Lys Thr His Pro Leu Met Asp Glu 385 390 395 400 gca gtg ccc tec ate ttc aac agg cca tgg ttc ctg aga aca arg gtc 1905 Ala Val Pro Ser He Phe Asn Arg Pro Trp Phe Leu Arg Thr Met Val 405 410 415 aga tac cgc ctt ace aaa att gca gtg gac aca get get ggg cca tat 1953 Arg Tyr Arg Leu Thr Lys He Ala Val Asp Thr Ala Ala Gly Pro Tyr 420 425 430 cag aat cac act gtg gtt ttt ctg gga tea gag aag gga ate ate ttg 2001 Gin Asn His Thr Val Val Phe Leu Gly Ser Glu Lys Gly He He Leu 435 440 445 aag ttt ttg gcc aga ata gga aat agt ggt ttt eta aat gac age ctt 2049 Lys Phe Leu Ala Arg He Gly Asn Ser Gly Phe Leu Asn Asp Ser Leu 450 455 460 ttc ctg gag gag atg agt gtt tac aac tct gaa aaa tgc age tat gat 2097 15 Phe Leu Glu Glu Met Ser Val Tyr Asn Ser Glu Lys Cys Ser Tyr Asp 465 470 475 480 gga gtc gaa gac aaa agg ate atg ggc atg cag ctg gac aga gca age 2145 Gly Val Glu Asp Lys Arg He Met Gly Met Gin Leu Asp Arg Ala Ser 485 490 495 age tct ctg tat gtt gcg rtc tct ace tgt gtg ata aag gtt ccc ctt 2193 Ser Ser Leu Tyr Val Ala Phe Ser Thr Cys Val He Lys Val Pro Leu 500 505 510 ggc egg tgt gaa cga cat ggg aag tgt aaa aaa ace tgt att gcc tec 2241 Gly Arg Cys Glu Arg His Gly Lys Cys Lys Lys Thr Cys He Ala Ser 515 520 525 aga gac cca tat tgt gga tgg ata aag gaa ggt ggt gcc tgc age cat 2289 Arg Asp Pro Tyr Cys Gly Trp He Lys Glu Gly Gly Ala Cys Ser His 530 535 540 tta tea ccc aac age aga ctg act ttt gag cag gac ata gag cgt ggc 2337 Leu Ser Pro Asn Ser Arg Leu Thr Phe Glu Gin Asp He Glu Arg Gly 545 550 555 560 aat aca gat ggt ctg ggg gac tgt cac aat tec ttt gtg gca ctg aat 2385 Asn Thr Asp Gly Leu Gly Asp Cys His Asn Ser Phe Val Ala Leu Asn 565 570 575 ggg cat tec agt tec etc ttg ccc age aca ace aca tea gat teg acg 2433 Gly His Ser Ser Ser Leu Leu Pro Ser Thr Thr Thr Ser Asp Ser Thr 580 585 590 get caa gag ggg tat gag tct agg gga gga atg ctg gac tgg aag cat 2481 Ala Gin Glu Gly Tyr Glu Ser Arg Gly Gly Met Leu Asp Trp Lys His 595 600 605 ctg ctt gac tea cct gac age aca gac cct ttg ggg gca gtg tct tec 2529 Leu Leu Asp Ser Pro Asp Ser Thr Asp Pro Leu Gly Ala Val Ser Ser 610 615 620 cat aat cac caa gac aag aag gga gtg att egg gaa agt tac etc aaa 2577 His Asn His Gin Asp Lys Lys Gly Val He Arg Glu Ser Tyr Leu Lys 625 630 635 640 ggc cac gac cag ctg gtt ccc gtc ace etc ttg gcc att gca gtc ate 2625 Gly His Asp Gin Leu Val Pro Val Thr Leu Leu Ala He Ala Val He 645 650 655 ctg get ttc gtc atg ggg gcc gtc ttc teg ggc ate ace gtc tac tgc 2673 16 Leu Ala Phe Val Met Gly Ala Val Phe Ser Gly He Thr Val Tyr Cys 660 665 670 gtc tgt gat cat egg cgc aaa gac gtg get gtg grg cag cgc aag gag 2721 Val Cys Asp His Arg Arg Lys Asp Val Ala Val Val Gin Arg Lys Glu 675 680 685 aag gag crc ace cac teg cgc egg ggc tec atg age age gtc ace aag 2769 Lys Glu Leu Thr His Ser Arg Arg Gly Ser Met Ser Ser Val Thr Lys 690 695 700 etc age ggc etc ttt ggg gac act caa tec aaa gac cca aag ccg gag 2817 Leu Ser Gly Leu Phe Gly Asp Thr Gin Ser Lys Asp Pro Lys Pro Glu 705 710 715 720 gcc ate etc acg cca etc atg cac aac ggc aag etc gcc act ccc ggc 2865 Ala He Leu Thr Pro Leu Met His Asn Gly Lys Leu Ala Thr Pro Gly 725 730 735 aac acg gcc aag atg etc att aaa gca gac cag cac cac ctg gac ctg 2913 Asn Thr Ala Lys Met Leu He Lys Ala Asp Gin His His Leu Asp Leu 740 745 750 acg gcc etc ccc ace cca gag tea ace cca acg ctg cag cag aag egg 2961 Thr Ala Leu Pro Thr Pro Glu Ser Thr Pro Thr Leu Gin Gin Lys Arg 755 760 765 aag ccc age cgc ggc age cgc gag tgg gag agg aac cag aac etc ate 3009 Lys Pro Ser Arg Gly Ser Arg Glu Trp Glu Arg Asn Gin Asn Leu He 770 775 780 aat gcc tgc aca aag gac atg ccc ccc atg ggc tec cct gtg att ccc 3057 Asn Ala Cys Thr Lys Asp Met Pro Pro Met Gly Ser Pro Val He Pro 785 790 795 800 acg gac ctg ccc ctg egg gcc tec ccc age cac ate ccc age gtg gtg 3105 Thr Asp Leu Pro Leu Arg Ala Ser Pro Ser His He Pro Ser Val Val 805 810 815 gtc ctg ccc ate acg cag cag ggc tac cag cat gag tac gtg gac cag 3153 Val Leu Pro He Thr Gin Gin Gly Tyr Gin His Glu Tyr Val Asp Gin 820 825 830 ccc aaa atg age gag gtg gcc cag atg gcg ctg gag gac cag gcc gcc 3201 Pro Lys Met Ser Glu Val Ala Gin Met Ala Leu Glu Asp Gin Ala Ala 835 840 845 aca ctg gag tat aag ace ate aag gaa cat etc age age aag agt ccc 3249 17 Thr Leu Glu Tyr Lys Thr He Lys Glu H s Leu Ser Ser Lys Ser Pro 850 855 860 aac cat ggg gtg aac ctt gtg gag aac ctg gac age ctg ccc ccc aaa 3297 Asn His Gly Val Asn Leu Val Glu Asn Leu Asp Ser Leu Pro Pro Lys 865 870 875 880 gtt cca cag egg gag gcc tec ctg ggr ccc ccg gga gcc tec ctg tct 3345 Val Pro Gin Arg Glu Ala Ser Leu Gly Pro Pro Gly Ala Ser Leu Ser 885 890 895 cag ace ggt eta age aag egg ctg gaa atg cac cac tec tct tec tac 3393 Gin Thr Gly Leu Ser Lys Arg Leu Glu Met His His Ser Ser Ser Tyr 900 905 910 ggg gtt gac tat aag agg age tac ccc acg aac teg etc acg aga age 3441 Gly Val Asp Tyr Lys Arg Ser Tyr Pro Thr Asn Ser Leu Thr Arg Ser 915 920 925 cac cag gcc ace act etc aaa aga aac aac act aac tec tec aat tec 3489 His Gin Ala Thr Thr Leu Lys Arg Asn Asn Thr Asn Ser Ser Asn Ser 930 935 940 tct cac etc tec aga aac cag age ttt ggc agg gga gac aac ccg ccg 3537 Ser His Leu Ser Arg Asn Gin Ser Phe Gly Arg Gly Asp Asn Pro Pro 945 950 955 960 ccc gcc ccg cag agg gtg gac tec ate cag gtg cac age tec cag cca 3585 Pro Ala Pro Gin Arg Val Asp Ser He Gin Val His Ser Ser Gin Pro 965 970 975 tct ggc cag gcc gtg act gtc teg agg cag ccc age etc aac gcc tac 3633 Ser Gly Gin Ala Val Thr Val Ser Arg Gin Pro Ser Leu Asn Ala Tyr 980 985 990 aac tea ctg aca agg teg ggg ctg aag cgt acg ccc teg eta aag ccg 3681 Asn Ser Leu Thr Arg Ser Gly Leu Lys Arg Thr Pro Ser Leu Lys Pro 995 1000 1005 gac gta ccc ccc aaa cca tec ttt get ccc ctt tec aca tec atg aag 3729 Asp Val Pro Pro Lys Pro Ser Phe Ala Pro Leu Ser Thr Ser Met Lys 1010 1015 1020 ccc aat gat gcg tgt aca taa tcccaggggg agggggtcag gtgtcgaacc 3780 Pro Asn Asp Ala Cys Thr 1025 1030 agcaggeaag gegaggtgee egctcagetc agcaaggttc teaaetgcct cgagtaecca 3840 ccagaccaag aaggcctgcg gc 3862 <210> 7 <211> 1030 <212> PRT <213> Homo sapiens <400> 7 Met Arg Ser Glu Ala Leu Leu Leu Tyr Phe Thr Leu Leu His Phe Ala 1 5 10 15 Gly Ala Gly Phe Pro Glu Asp Ser Glu Pro He Ser He Ser His Gly 20 25 30 Asn Tyr Thr Lys Gin Tyr Pro Val Phe Val Gly His Lys Pro Gly Arg 35 40 45 Asn Thr Thr Gin Arg His Arg Leu Asp He Gin Met He Met He Met 50 55 60 Asn Gly Thr Leu Tyr He Ala Ala Arg Asp His He Tyr Thr Val Asp 65 70 75 80 He Asp Thr Ser His Thr Glu Glu He Tyr Cys Ser Lys Lys Leu Thr 85 90 95 Trp Lys Ser Arg Gin Ala Asp Val Asp Thr Cys Arg Met Lys Gly Lys 100 105 110 His Lys Asp Glu Cys His Asn Phe He Lys Val Leu Leu Lys Lys Asn 115 120 125 Asp Asp Ala Leu Phe Val Cys Gly Thr Asn Ala Phe Asn Pro Ser Cys 130 135 140 Arg Asn Tyr Lys Met Asp Thr Leu Glu Pro Phe Gly Asp Glu Phe Ser 145 150 155 160 Gly Met Ala Arg Cys Pro Tyr Asp Ala Lys His Ala Asn Val Ala Leu 165 170 175 Phe Ala Asp Gly Lys Leu Tyr Ser Ala Thr Val Thr Asp Phe Leu Ala 180 185 190 He Asp Ala Val He Tyr Arg Ser Leu Gly Glu Ser Pro Thr Leu Arg 195 200 205 19 Thr Val Lys His Asp Ser Lys Trp Leu Lys Glu Pro Tyr Phe Val Gin 210 215 220 Ala Val Asp Tyr Gly Asp Tyr He Tyr Phe Phe Phe Arg Glu He Ala 225 230 235 240 Val Glu Tyr Asn Thr Met Gly Lys Val Val Phe Pro Arg Val Ala Gin 245 250 255 Val Cys Lys Asn Asp Met Gly Gly Ser Gin Arg Val Leu Glu Lys Gin 260 265 270 Trp Thr Ser Phe Leu Lys Ala Arg Leu Asn Cys Ser Val Pro Gly Asp 275 280 285 Ser His Phe Tyr Phe Asn He Leu Gin Ala Val Thr Asp Val He Arg 290 295 300 He Asn Gly Arg Asp Val Val Leu Ala Thr Phe Ser Thr Pro Tyr Asn 305 310 315 320 Ser He Pro Gly Ser Ala Val Cys Ala Tyr Asp Met Leu Asp He Ala 325 330 335 Ser Val Phe Thr Gly Arg Phe Lys Glu Gin Lys Ser Pro Asp Ser Thr 340 345 350 Trp Thr Pro Val Pro Asp Glu Arg Val Pro Lys Pro Arg Pro Gly Cys 355 360 365 Cys Ala Gly Ser Ser Ser Leu Glu Arg Tyr Ala Thr Ser Asn Glu Phe 370 375 380 Pro Asp Asp Thr Leu Asn Phe He Lys Thr His Pro Leu Met Asp Glu 385 390 395 400 Ala Val Pro Ser He Phe Asn Arg Pro Trp Phe Leu Arg Thr Met Val 405 410 415 Arg Tyr Arg Leu Thr Lys He Ala Val Asp Thr Ala Ala Gly Pro Tyr 420 425 430 Gin Asn His Thr Val Val Phe Leu Gly Ser Glu Lys Gly He He Leu 435 440 445 Lys Phe Leu Ala Arg He Gly Asn Ser Gly Phe Leu Asn Asp Ser Leu 450 455 460 20 Phe Leu Glu Glu Met Ser Val Tyr Asn Ser Glu Lys Cys Ser Tyr Asp 465 470 475 480 Gly Val Glu Asp Lys Arg He Met Gly Met Gin Leu Asp Arg Ala Ser 485 490 495 Ser Ser Leu Tyr Val Ala Phe Ser Thr Cys Val He Lys Val Pro Leu 500 505 510 Gly Arg Cys Glu Arg His Gly Lys Cys Lys Lys Thr Cys He Ala Ser 515 520 525 Arg Asp Pro Tyr Cys Gly Trp He Lys Glu Gly Gly Ala Cys Ser His 530 535 540 Leu Ser Pro Asn Ser Arg Leu Thr Phe Glu Gin Asp He Glu Arg Gly 545 550 555 560 Asn Thr Asp Gly Leu Gly Asp Cys His Asn Ser Phe Val Ala Leu Asn 565 570 575 Gly His Ser Ser Ser Leu Leu Pro Ser Thr Thr Thr Ser Asp Ser Thr 580 585 590 Ala Gin Glu Gly Tyr Glu Ser Arg Gly Gly Met Leu Asp Trp Lys His 595 600 605 Leu Leu Asp Ser Pro Asp Ser Thr Asp Pro Leu Gly Ala Val Ser Ser 610 615 620 His Asn His Gin Asp Lys Lys Gly Val He Arg Glu Ser Tyr Leu Lys 625 630 635 640 Gly His Asp Gin Leu Val Pro Val Thr Leu Leu Ala He Ala Val He 645 650 655 Leu Ala Phe Val Met Gly Ala Val Phe Ser Gly He Thr Val Tyr Cys 660 665 670 Val Cys Asp His Arg Arg Lys Asp Val Ala Val Val Gin Arg Lys Glu 675 680 685 Lys Glu Leu Thr His Ser Arg Arg Gly Ser Met Ser Ser Val Thr Lys 690 695 700 Leu Ser Gly Leu Phe Gly Asp Thr Gin Ser Lys Asp Pro Lys Pro Glu 705 710 715 720 21 Ala He Leu Thr Pro Leu Met His Asn Gly Lys Leu Ala Thr Pro Gly 725 730 735 Asn Thr Ala Lys Met Leu He Lys Ala Asp Gin His His Leu Asp Leu 740 745 750 Thr Ala Leu Pro Thr Pro Glu Ser Thr Pro Thr Leu Gin Gin Lys Arg 755 760 765 Lys Pro Ser Arg Gly Ser Arg Glu Trp Glu Arg Asn Gin Asn Leu He 770 775 780 Asn Ala Cys Thr Lys Asp Met Pro Pro Met Gly Ser Pro Val He Pro 785 790 795 800 Thr Asp Leu Pro Leu Arg Ala Ser Pro Ser His He Pro Ser Val Val 805 810 815 Val Leu Pro He Thr Gin Gin Gly Tyr Gin His Glu Tyr Val Asp Gin 820 825 830 Pro Lys Met Ser Glu Val Ala Gin Met Ala Leu Glu Asp Gin Ala Ala 835 840 845 Thr Leu Glu Tyr Lys Thr He Lys Glu His Leu Ser Ser Lys Ser Pro 850 855 860 Asn His Gly Val Asn Leu Val Glu Asn Leu Asp Ser Leu Pro Pro Lys 865 870 875 880 Val Pro Gin Arg Glu Ala Ser Leu Gly Pro Pro Gly Ala Ser Leu Ser 885 890 895 Gin Thr Gly Leu Ser Lys Arg Leu Glu Met His His Ser Ser Ser Tyr 900 905 910 Gly Val Asp Tyr Lys Arg Ser Tyr Pro Thr Asn Ser Leu Thr Arg Ser 915 920 925 His Gin Ala Thr Thr Leu Lys Arg Asn Asn Thr Asn Ser Ser Asn Ser 930 935 940 Ser His Leu Ser Arg Asn Gin Ser Phe Gly Arg Gly Asp Asn Pro Pro 945 950 955 960 Pro Ala Pro Gin Arg Val Asp Ser He Gin Val His Ser Ser Gin Pro 965 970 975 22 Ser Gly Gin Ala Val Thr Val Ser Arg Gin Pro Ser Leu Asn Ala Tyr 980 985 990 Asn Ser Leu Thr Arg Ser Gly Leu Lys Arg Thr Pro Ser Leu Lys Pro 995 1000 1005 Asp Val Pro Pro Lys Pro Ser Phe Ala Pro Leu Ser Thr Ser Met Lys 1010 1015 1020 Pro Asn Asp Ala Cys Thr 025 1030 23

Claims: Claims 1 . Nucleic acid coding for human semaphorin 6A- 1 comprising: (a) the nucleotide sequence shown in SEQ ID NO: 1 , (b) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO: 1 within the degeneration of the genetic code, or (c) a sequence which hybridizes with the sequences of (a) or/and (b) under stringent conditions. 2. Nucleic acid coding for a binding domain of human semaphorin 6A- 1 comprising: (a) the nucleotide sequence shown in SEQ ID NO:3, (b) a sequence corresponding to the nucleotide sequence shown in SEQ ID NO:3 within the degeneration of the genetic code, or (c) a sequence which hybridizes with the sequences of (a) or/and (b) under stringent conditions. 3. Nucleic acid according to claim 1 or 2, characterized in that it has a homology greater than 80% to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:3. 4. Modified nucleic acid or nucleic acid analog having a nucleotide sequence according to claims 1 -3, or a section having at least 1 2 bases therefrom. 5. A nucleic acid which encodes a protein having a semaphorin domain and which hybridizes under stringent conditions to a nucleic acid comprising the nucleotide sequence shown in SEQ ID NO : 1 . 6. Nucleic acid according to any of the preceding claims, which encodes a protein inhibiting neurite outgrowth. 7. Nucleic acid according to claim 6, which encodes a protein inhibiting neurite outgrowth of CNS-neuron. 8. Recombinant vector, characterized in that it contains at least one copy of a nucleic acid according to claims 1 -7, or a section therefrom. 9. Vector according to claim 8, characterized in that it is a eukaryotic vector. 1 0. Cell, characterized in that it is transformed with a nucleic acid according to any of claims 1 -7 or with a vector according to claim 8 or 9. 1 1 . Polypeptide encoded by a nucleic acid according to claims 1 -7. 1 2. Polypeptide according to claim 1 1 being a fusion protein comprising a polypeptide encoded by a nucleic acid according to claims 1 -7 and at least one further polypeptide. 1 3. Use of the polypeptide according to claim 1 1 or 1 2 or of fragments of said polypeptide as immunogen for the production of antibodies. 1 4. Antibodies against a polypeptide according to claim 1 1 or 1 2. 1 5. Pharmaceutical composition comprising: (a) a nucleic acid according to any of claims 1 -7, (b) a recombinant vector according to claim 8 or 9, (c) a cell according to claim 1 0, (d) a polypeptide according to claim 11 or 12, or/and (e) an antibody according to claim 14. 16. Use of a peptide according to claim 11 or 12 for the preparation of a pharmaceutical composition. 17. Use of a composition according to claim 15 as diagnostic agent. 18. Use of a composition according to claim 15 for the production of a therapeutic agent. 19. Use according to claim 18 for the modulation of the immune system. 20. Use according to any of claims 17-19 in gene therapy. 21. Use according to any of claims 17-20 for effecting differentiation, cytoskeletal stabilization and/or plasticity.

Inventors: BEHL CHRISTIAN, KLOSTERMANN ANDREAS, BEHL, CHRISTIAN, KLOSTERMANN, ANDREAS
Applicants: BEHL CHRISTIAN, KLOSTERMANN ANDREAS, MAX PLANCK GESELLSCHAFT, BEHL, CHRISTIAN, KLOSTERMANN, ANDREAS, MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Application year: 1999
Main classification: C12N15
IPC codes: A61K38, A61K48, C07K14, C12N15